Thanks algorithm. I also joined in Telegram, ready to learn more and exchange views there. The English conversion you gave on the Fraunhofer synopsis is quite clear to the reader about what ATMP therapy they are giving (DCVaxL) and whom they are running it for (NWBO). LP is still on the driver seat. The report reads they are done enrolling statistically enough patients for the phase 3 trial in 2015 who are treated with DCVaxL in multiple doses that last to 2018. The report concludes NWBO will evaluate the trial once all doses are administered. It is already middle of April and depending on the maximum number of doses manufactured for respective patients depending on their tumor load, hopefully most of those patients started in 2015 might be already done dosed, only a few still left to have the last one or two doses administered, imo. They are reporting the medicinal product is still DCVaxL cells that is manufactured here meeting their Advanced Therapy Medicinal Product (ATMP) standard meaning the advancement what Doc Logic has been telling us all along in filtering and perfecting the right cells has in fact been happening here. The Germans feel proud about this advancement in manufacturing and it seems like the patients are doing extremely well. Out of the statistical strength of 87 recruited here how many crossovered? how many are still alive? Is 2018 Spring Refresh done in this site? If yes, the PFS/OS blended data from this site must also be available now and the data from this site alone should fetch us the FDA approval based on one of those fast approval single site minimum convincing guidance FDA released - why not? So like our multi pronged DC Cells in multi pathways, LP has so many fronts that she can get AA it seems like, imo. So while the approvals in multi countries are in the wings, I am again very comfortable holding my shares long. Go NWBO!
News 
Market Data 
Discover 
